Three Hyderabad-based pharmaceutical companies have entered into an agreement with the UN-backed Medicines Patent Pool (MPP), headquartered in Geneva, to manufacture and supply a generic version of Pfizer’s Covid-19 oral treatment Nirmatrelvir.
Aurobindo Pharma announced the signing of a sub-license agreement with MPP. MPP had previously signed a voluntary licencing agreement with Pfizer to sub-license this Covid-19 treatment product to qualified generic drugmakers.
Nirmatrelvir along with ritonavir co-pack has been granted emergency use/conditional approval for Covid-19 treatment in specific populations by the US Food and Drug Administration and the UK Medicines and Healthcare products Regulatory Agency (UKMHRA and about 50 different countries).
ALSO READ: COVID-19: Concern raises in Hyderabad due to spike in infections in China
Aurobindo Pharma has already developed and commercialised Ritonavir, which is used in conjunction with Nirmatrelvir as a booster. After registration and approval in various countries, including India, we will soon make it commercially available at an affordable price, said K Nithyananda Reddy, Vice Chairman and Managing Director, Aurobindo Pharma.
MSN Group has also entered into a licencing agreement with MPP and will launch the product in India under the brand name ‘PAXVID’ after receiving approval from DCGI. MPP has granted Granules India a licence to manufacture and market generic versions of Pfizer’s oral treatment.
The product will be manufactured in India at Granules manufacturing facilities that have been approved by global regulatory agencies such as the USFDA.
SMS Pharmaceuticals also have received licences from Medicines Patent Pool (MPP) to develop and supply a generic version of Nirmatrelvir.
According to SMS Pharma, the oral treatment reduced the risk of Covid-19-related hospitalisation or death for any reason by 89 per cent when compared to placebo in a Pfizer conducted Phase 2/3 study.
Nirmatrelvir 300 mg (two 150mg tablets) with ritonavir 100mg (one tablet) twice daily for five days is the recommended dose.
(This story has been sourced from a third-party syndicated feed, agencies. Raavi Media accepts no responsibility or liability for the dependability, trustworthiness, reliability, and data of the text. Raavi Media management/ythisnews.com reserves the sole right to alter, delete or remove (without notice) the content at its absolute discretion for any reason whatsoever.)
